enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Sanjay Shrivastava acquired 5,400 shares of the business’s stock in a transaction dated Tuesday, December 24th. The shares were bought at an average cost of $2.90 per share, for a total transaction of $15,660.00. Following the transaction, the director now directly owns 9,288 shares of the company’s stock, valued at approximately $26,935.20. This trade represents a 138.89 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

enVVeno Medical Trading Up 8.5 %

NVNO traded up $0.24 on Thursday, hitting $3.06. 429,034 shares of the company were exchanged, compared to its average volume of 113,650. The firm has a 50-day moving average price of $3.19 and a two-hundred day moving average price of $4.31. enVVeno Medical Corporation has a twelve month low of $2.45 and a twelve month high of $6.97. The company has a market cap of $53.66 million, a price-to-earnings ratio of -2.37 and a beta of 1.22.

enVVeno Medical (NASDAQ:NVNO) last released its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Equities analysts expect that enVVeno Medical Corporation will post -1.3 EPS for the current year.

Hedge Funds Weigh In On enVVeno Medical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Hohimer Wealth Management LLC purchased a new stake in enVVeno Medical during the 3rd quarter worth about $286,000. Maven Securities LTD purchased a new position in enVVeno Medical in the third quarter valued at approximately $295,000. Westside Investment Management Inc. increased its stake in enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after purchasing an additional 49,613 shares during the last quarter. Corsair Capital Management L.P. acquired a new stake in enVVeno Medical during the third quarter worth approximately $390,000. Finally, Geode Capital Management LLC lifted its position in shares of enVVeno Medical by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after buying an additional 10,902 shares during the last quarter. Institutional investors and hedge funds own 34.71% of the company’s stock.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).